Apoptosis-inducing effects of two anthraquinones from Hedyotis diffusa Willd.

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 6, 2008, Pages 1075-1078

  Shi, Ying ^a   Wang, Chen Hui ^a   Gong, Xing Guo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Anthraquinone; Apoptosis; C src protein tyrosine kinase; Caspase 3; Hedyotis diffusa; Mitochondrial membrane potential

Indexed keywords

1 METHOXY 2 HYDROXYANTHRAQUINONE; 2 HYDROXY 3 METHYLANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; CASPASE 3; HEDYOTIS DIFFUSA EXTRACT; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL;

ANNEXIN A5; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BISBENZIMIDE; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORING AGENTS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HEDYOTIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; RHODAMINE 123; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; SRC-FAMILY KINASES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 45749145862     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1075     Document Type: Article

References (20)

1. Wu Q., J. Chin. Med. Mater., 23, 654-657 (2000).
2. Che J. C., Xin N., Feng J., J. Anhui Agric. Sci., 35, 6162-6167 (2007).
3. Liao L. L., Chen C. H., Chen G. C., Taiwan Yi Xue Hui Za Zhi., 78, 658-660 (1979).
4. Hu L., Wang H. Q., Cui N. J., Hu C. X., Li J. G., Ye L. P., J. GuangZhou Univ. Trad. Chin. Med., 24, 313-316 (2007).
5. Zhang S. D., Fang Y. X., Chen M. M., Huang J. P., Zhang K., Zhong Yao Cai, 30, 179-182 (2007).
6. Chen L. P., Yang X. S., Wei X., Wang F. S., J. JiangXi Univ. Trad. Chin. Med., 6, 53-55 (2005).
7. Summy J. M., Gallick G. E., Cancer Metastasis Rev., 22, 337-358 (2003).
8. Muthuswamy S. K., Muller W. J., Adv. Cancer Res., 64, 111-123 (1994).
9. Park S. I., Shah A. N., Zhang J., Gallick G. E., Expert Opin. Ther. Targets, 11, 1207-1217 (2007).
10. Blume-Jensen P., Hunter T., Nature (London), 411, 355-365 (2001).
11. Rosen N., Bolen J. B., Schwartz A. M., Cohen P., Deseau V., Israel M. A., J. Biol. Chem., 261, 13754-13759 (1986).
12. Myoui A., Nishimura R., Williams P. J., Tamura D., Michigami T., Mundy G. R., Yoneda T., Cancer Res., 63, 5028-5033 (2003).
13. Al-Obeidi F. A., Lam K. S., Oncogene, 19, 5690-5701 (2000).
14. Madhusudan S., Ganesan T. S., Clin. Biochem., 7, 618-635 (2004).
15. Tai D. F., Lin Y. M., Chen F. C., Huaxue, 3, 60-61 (1979).
16. Windham T. C., Parikh N. U., Siwak D. R., Summy J. M., McConkey D. J., Kraker A. J., Gallick G. E., Oncogene, 21, 7797-7807 (2002).
17. Rego A. C., Vesce S., Nicholls D. G., Cell Death Differ., 8, 995-1003 (2001).
18. Tsao A. S., He D., Saigal B., Liu S., Lee J. J., Bakkannagari S., Ordonez N. G., Hong W. K., Wistuba I., Johnson F. M., Mol. Cancer Ther., 6, 1962-1972 (2007).
19. Lee H. Z., Br. J. Pharmacol., 134, 11-20 (2001).
20. Wang X. D., Gu L. Q., Wu J. Y., Biol. Pharm. Bull., 30, 1113-1116 (2007).